Skip to main content

Table 1 Correlation between CMTM6/vimentin protein expression and the clinicopathological characteristics of patients with HCC (n = 90)

From: CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells

Features Total number (n = 90) Expression of CMTM6 P-value Expression of vimentin P-value
Low High Low High
Age(years)
 < 60 68 21 (30.9%) 47 (69.1%) 0.386 24 (35.3%) 44 (64.7%) 0.219
 ≥ 60 22 9 (40.9%) 13 (59.1%)   11 (50.0%) 11 (50.0%)  
Gender
 Male 80 27 (33.8%) 53 (66.3%) 0.813 32 (40.0%) 48 (60.0%) 0.541
 Female 10 3 (30.0%) 7 (70.0%)   3 (30.0%) 7 (70.0%)  
Microvascular invasion
 Present 54 23 (42.6%) 31 (57.4%) 0.04* 26 (48.1%) 35 (51.9%) 0.013*
 Absent 26 5 (19.2%) 21 (80.8%)   5 (19.2%) 21 (80.8%)  
Tumour size(cm)
 < 5 51 22 (43.1%) 29 (56.9%) 0.024* 25 (49.0%) 26 (51.0%) 0.024*
 ≥ 5 39 8 (20.5%) 31 (79.5%)   10 (25.6%) 29 (74.4%)  
Differentiation
 Well 15 9 (60.0%) 6 (40.0%) 0.039* 12 (80.0%) 3 (20.0%) 0.001*
 Moderate 38 10 (26.3%) 28 (73.7%)   11 (28.9%) 27 (71.1%)  
 Poor 31 8 (25.8%) 23 (74.2%)   8 (25.8%) 23 (74.2%)  
HBsAg
 Negative 19 11 (57.9%) 8 (42.1%) 0.012* 6 (31.6%) 13 (68.4%) 0.436
 Positive 70 19 (27.1%) 51 (72.9%)   29 (41.4%) 41 (58.6%)  
Serum AFP level (ng/ml)
 < 25 39 9 (23.1%) 30 (76.9%) 0.061 16 (41.0%) 23 (59.0%) 0.772
 ≥ 25 50 21 (42.0%) 29 (58.0%)   19 (38.0%) 31 (62.0%)  
TNM stage
 I + II 78 29 (37.2%) 49 (62.8%) 0.048* 35 (44.9%) 43 (55.1%) 0.003*
 III + IV 12 1 (8.3%) 11 (91.7%)   0 (0.0%) 12 (100.0%)  
  1. * p < 0.05